Fundraising Fox

IpiNovyx Bio

West Nyack, US · Founded 2021 · Delaware corporation · 4 employees on LinkedIn · 2 known investors

IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases. Its technology originated from research at Weill Cornell Medicine and the Hospital for Special Surgery, and it is advancing these preclinical programs toward clinical applications.

BiotechHealthtechMedical Devices

Founders & leadership

IpiNovyx Bio was founded in 2021 by Gang Lin, Carl Nathan, and Franck Barrat.

GL
Gang LinScientific Founder
CN
Carl NathanScientific Founder
FBFranck Barrat
Franck BarratinScientific Founder
MA
Marc AppelNamed on SEC filing
LG
Lutz GiebelNamed on SEC filing
JG
James GrahamNamed on SEC filing

Investors · 2

Pathway BioventuresChicago
Alexandriareported · 2 sourcesPasadena

Reported raises · per SEC filings

Form D private placements

$7M disclosed across 1 round · 2021

▶$7MraisedOct 2021 · 12 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Marc AppelExecutive Officer, Director
  • Lutz GiebelDirector
  • James GrahamDirector
Offering amount
$10M
Amount sold
$7M
First sale
Sep 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

IpiNovyx Bio Awarded NIH Catalyze Award to Advance Novel Proteasome Therapeutic for Systemic Sclerosis-Associated Interstitial Lung Diseaseorangegrovebio.com · May 2026IpiNovyx Bio Closes $10 Million Seed Financing to Advance Best-in-Class Immunoproteasome Inhibitors Toward First-in-Human Clinical Studiesnews.hss.edu · Oct 2021IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platformorangegrovebio.com · Oct 2021Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry | Fierce Biotechfiercebiotech.com · Oct 2021IpiNovyx Bio, Inc. announced that it has received $10 million in funding from Viva BioInnovator, Alexandria Venture Investments, LLC, Opaleye Management Inc., Eli Lilly and Company, Orange Grove Bio LLC and other investors | MarketScreener Canadaca.marketscreener.com · Oct 2021IpiNovyx Bio, Inc. announced that it expects to receive $10.000093 million in funding | MarketScreenermarketscreener.com · Sep 2021

Frequently asked questions

What does IpiNovyx Bio do?
IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases. Its technology originated from research at Weill Cornell Medicine and the Hospital for Special Surgery, and it is advancing these preclinical programs toward clinical applications.
Who founded IpiNovyx Bio?
IpiNovyx Bio was founded by Gang Lin, Carl Nathan, Franck Barrat in 2021.
Who are IpiNovyx Bio's investors?
IpiNovyx Bio's investors include Pathway Bioventures, Alexandria.
How much funding has IpiNovyx Bio raised?
IpiNovyx Bio has disclosed $7M raised across 1 round.
Where is IpiNovyx Bio headquartered?
IpiNovyx Bio is headquartered in West Nyack, US.